Standardized
Corosolic Acid (1%) Study
Study
In 1998, a crossover, placebo-controlled clinical study was
conducted at the Tokyo Jikeikai Medical School in Japan with
24 subjects. The criteria for including subjects in this study
were mild case of insulin independent diabetes, inability
to tolerate glucose burden, glucose levels of 110mg/deciliter
(fasting level) and subjects older than 20 years of age.
The
subjects were given orally either a placebo or 3 tablets of
250mg each, after each meal three times daily. The daily total
dose of Corosolic acid was 0.16 mg, the active ingredient
of GlucosolT. The results of this study clearly demonstrate
that GlucosolT is effective in reducing blood glucose levels
even in short-term (4 weeks) treatment, with no signs of adverse
effects.
Furthermore,
even a one-time dose leaves a memory-effect for blood glucose
control. Compared to the placebo group, a statistically significant
drop in the average blood glucose level is observed with the
administration of GlucosolT Blood glucose level dropped from
153.9 mg/deciliter, before the GlucosolT dose, to 133.1 mg/deciliter,
after the dose.
